Vinge advises Axcel in connection with the acquisition of Oral Care, a leading dental care provider in Sweden and Norway.

Founded in Stockholm, Sweden, in 1989, Oral Care pioneered Swedish mobile dental care, which entails treatment of elderly and disabled patients in their own homes, typically nursing homes. In 2015, Oral Care leveraged its leading mobile practice to establish a clinic footprint in Sweden. Since then, the company has expanded its clinic network by acquiring and integrating well-performing clinics in Sweden and Norway. Oral Care currently operates 12 clinics in Sweden and two in Norway. Furthermore, Oral Care is Sweden’s largest private provider of mobile dental care, active in seven regions in central and southern Sweden.

The acquisition is subject to approval from applicable competition authority.

Vinge’s team consisted of Christina Kokko, Johanna Wiberg, Elsie Nassar, Nando Basic and Ida Redander (M&A), Christoffer Nordin (Commercial Agreements, Regulatory and Permits), Mikael Ståhl, Linn Adelwald and Ellen Flygt (Banking and Financing), Frida Ställborn (Real Estate and Environmental), Julia Löfqvist (Compliance), Lina André (Employment), Nicklas Thorgerzon (IT and GDPR), Michael Montner and Ian Jonsson (Intellectual Property), Johan Wahlbom and Victoria Fredén (Merger filing) and Jessica Henning (Project and VDR Assistant).

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025